---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-076460"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:30:37.641428+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio receives FDA clearance for ADI-270 IND in renal cell carcinoma; Phase 1 trial planned for H2 2024

## Summary
- ADI-270 is the first gamma delta 1 CAR T cell therapy to enter clinical trials for solid tumors.
- Phase 1 multicenter, open-label trial in relapsed/refractory clear cell RCC to start in H2 2024; preliminary data expected H1 2025.
- ADI-270 is an armored allogeneic off-the-shelf CAR T targeting CD70+ cancers designed for high specificity and tumor infiltration.
- Trial will evaluate safety, tolerability, pharmacokinetics, overall response rate, duration of response, and disease control rate.

## SEC filing metadata
- accession: 0000950170-24-076460
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024076460/0000950170-24-076460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024076460/acet-20240624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-076460
- JSON: https://secwatch.observer/filing/0000950170-24-076460.json
- Plain text: https://secwatch.observer/filing/0000950170-24-076460.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.